OTC Markets OTCPK - Delayed Quote USD

Eisai Co., Ltd. (ESAIY)

7.24

0.00

(0.00%)

As of January 24 at 3:00:00 PM EST. Market Open.

EISAI TO BEGIN ENROLLING STUDY IN PATIENTS WITH NARCOLEPSY

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT06462404. Study sites are also planned for Canada.

PR Newswire 6 months ago

ESAIY
0.00%
ESALF
0.00%
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. L

PR Newswire 8 months ago

ESAIY
0.00%
ESALF
0.00%
BIIB
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai submitted to the U.S. Food and Drug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with

PR Newswire 9 months ago

BIIB

ESAIY
0.00%
ESALF
0.00%

Performance Overview

Return	ESAIY	Nikkei 225
YTD	+6.94%	-0.82%
1-Year	-38.12%	+10.67%
3-Year	-53.37%	+51.19%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Eisai Co., Ltd. (ESAIY)

EISAI TO BEGIN ENROLLING STUDY IN PATIENTS WITH NARCOLEPSY

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Performance Overview